TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02947971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental OFDI Imaging
Description: Imaging of the esophagus with a compact OFDI system and distal scanning catheter
Study: NCT02154061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IIV Flu Vaccine
Description: This is an FDA approved and tested Inactivated Flu Vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IIV Flu Vaccine
Description: This is an FDA approved and tested Inactivated Flu Vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: This is a standard antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: This is a standard antibiotic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: This is a standard antibiotic.
Study: NCT04697927

Intervention type: OTHER
Intervention: Questionnaires
Description: The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.

Intervention type: OTHER
Intervention: Questionnaires
Description: The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
Study: NCT03122587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation at 40 Hz
Description: Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active sham transcranial alternating current stimulation
Description: Active sham (placebo)
Study: NCT00955552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate and chondroitin sulphate association
Description: glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosamin DS® (Nutramax)
Description: oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
Study: NCT03857971

Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary Optical Coherence tomography
Description: Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
Study: NCT00810888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant activated factor VII
Description: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
Study: NCT04042545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPP001
Description: 1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
Study: NCT02849535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM care program
Description: PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
Study: NCT04349150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
Study: NCT03383146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected subcutaneously twice daily.
Study: NCT03476746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 foam
Description: A foam formulation of the active comparator Dovobet® ointment
Study: NCT03169023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Body Self Relations Questionnaire - Appearance Subscales
Description: -Gold-standard for the assessment of body image attitudes and contains 34 items

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer-Related Body Image Scale
Description: -13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cancer-Related Body Image Scale
Description: -13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer-Related Body Image Scale
Description: -13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire 9-Item Version
Description: -Widely used measure that assesses mood, including an item that screens for suicidality
Study: NCT03476746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovobet® ointment
Description: Ointment formulation containing same active ingredients as LEO 90100 foam
Study: NCT03169023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Health Questionnaire 9-Item Version
Description: -Widely used measure that assesses mood, including an item that screens for suicidality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire 9-Item Version
Description: -Widely used measure that assesses mood, including an item that screens for suicidality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iOTA
Description: -Washington University based intervention
Study: NCT05181319

Intervention type: OTHER
Intervention: occurrence of bronchopulmonary dysplasia
Description: We observe the incidence of bronchopulmonary dysplasia

Intervention type: OTHER
Intervention: occurrence of bronchopulmonary dysplasia
Description: We observe the incidence of bronchopulmonary dysplasia
Study: NCT01957345

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested.
Study: NCT03013881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-921
Description: 150 mg/vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-921
Description: 150 mg/vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-921
Description: 150 mg/vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-921
Description: 150 mg/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: 440 mg/vial
Study: NCT03416556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization to the glenohumeral joint
Description: The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: The manual contact condition
Description: During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No-contact condition
Description: During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
Study: NCT01215799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bafetinib
Description: Bafetinib 240 mg bid
Study: NCT01247779

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gynecologic surgery - standard coelioscopy
Description: lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gynecologic surgery - robot assisted coelioscopy
Description: lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
Study: NCT04104984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transvaginal ultrasound
Description: a transvaginal ultrasound is done to patient to determine cervical length

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Vaginal Suppository
Description: a progesterone vaginal suppository to prevent preterm labour

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cercalage
Description: Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital vaginal exam
Description: vaginal examination to detect short cervix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal ultrasound
Description: use abdominal ultrasound to measure cervical length

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocolytic Agents
Description: a medication is given to prevent uterine contraction
Study: NCT02826941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypothermia
Description: Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normothermia
Description: Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
Study: NCT01727349

Intervention type: OTHER
Group type: OTHER
Intervention: HbA1c measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Glucoce Tolerance Test
Description: Oral Glucoce Tolerance Test
Study: NCT02521077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 500 g ascorbic acid dissolved in 500 ml sterile water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 500 g ascorbic acid dissolved in 500 ml sterile water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Saline 0.9%
Study: NCT03164512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral or vaporized cannabidiol
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral or vaporized cannabidiol
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral or vaporized cannabidiol
Description: Acute drug exposure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule/vapor
Study: NCT02864966

Intervention type: DEVICE
Group type: OTHER
Intervention: Condom
Description: This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
Study: NCT01692353

Intervention type: OTHER
Intervention: Subject's usual brand (UB) tobacco product
Description: For SMK: UB of cigarettes; For MSC: UB of moist snuff

Intervention type: OTHER
Intervention: Subject's usual brand (UB) tobacco product
Description: For SMK: UB of cigarettes; For MSC: UB of moist snuff
Study: NCT03704441

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose
Study: NCT02521077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Saline 0.9%
Study: NCT00281008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
Study: NCT03704441

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: bupivacaine dose
Study: NCT01757782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sildenafil
Description: Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be \<10% of previous value and SpO2 was not increasing \>5 of previous value) and blood pressure remained stable
Study: NCT04425408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).
Description: Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
Study: NCT01757782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (distilled water)
Description: Distill water oral
Study: NCT00551538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro mix 75/25
Description: Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: SC injection, once-daily, given in conjunction with oral antidiabetic medications.
Study: NCT01091987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-pharmacological approach of insomnia
Description: education on sleep, sleep hygiene, stimulus control, cognitive techniques
Study: NCT04167306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate 1 mg b.i.d
Description: Capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate 1 mg b.i.d
Description: Capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride 150 mg b.i.d
Description: Capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride 150 mg b.i.d
Description: Capsules for oral use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for varenicline
Description: Capsules for oral use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for varenicline
Description: Capsules for oral use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for bupropion
Description: Capsules for oral use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for bupropion
Description: Capsules for oral use
Study: NCT02055430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrostomy insertion
Description: The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral double J ureteric stent
Description: The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
Study: NCT01508819

Intervention type: OTHER
Intervention: recommendations to admit to ICU all the patients included
Description: recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
Study: NCT03664050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group A 2.5 mg letrozole oral tablets
Description: 2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian drilling
Description: Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
Study: NCT00909584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezatiostat Hydrochloride
Description: Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
Study: NCT02130167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
Study: NCT03925935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-205
Description: Engineered human umbilical vein endothelial cells
Study: NCT01298778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duramorph 150
Description: Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duramorph 300
Description: Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses